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Abstract
Background: The proteasome is a multisubunit enzyme complex involved in protein degradation, which is
essential for many cellular processes. During inflammation, the constitutive subunits are replaced by their
inducible counterparts, resulting in the formation of the immunoproteasome.
Methods: We investigated the expression pattern of constitutive (β1, β5) and immunoproteasome (β1i, β5i)
subunits using immunohistochemistry in malformations of cortical development (MCD; focal cortical dysplasia
(FCD) IIa and b, cortical tubers from patients with tuberous sclerosis complex (TSC), and mild MCD (mMCD)).
Glial cells in culture were used to elucidate the mechanisms regulating immunoproteasome subunit expression.
Results: Increased expression was observed in both FCD II and TSC; β1, β1i, β5, and β5i were detected (within
cytosol and nucleus) in dysmorphic neurons, balloon/giant cells, and reactive astrocytes. Glial and neuronal
nuclear expression positively correlated with seizure frequency. Positive correlation was also observed between
the glial expression of constitutive and immunoproteasome subunits and IL-1β. Accordingly, the proteasome
subunit expression was modulated by IL-1β in human astrocytes in vitro. Expression of both constitutive and
immunoproteasome subunits in FCD II-derived astroglial cultures was negatively regulated by treatment with
the immunomodulatory drug rapamycin (inhibitor of the mammalian target of rapamycin (mTOR) pathway,
which is activated in both TSC and FCD II).
Conclusions: These observations support the dysregulation of the proteasome system in both FCD and TSC and
provide new insights on the mechanism of regulation the (immuno)proteasome in astrocytes and the molecular
links between inflammation, mTOR activation, and epilepsy.
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Background
The proteasome is an evolutionarily conserved multica-
talytic proteinase complex representing a major protein
degradation system, present in the nucleus and cytoplasm
of eukaryotic cells, that regulates diverse biological pro-
cesses essential for cell survival [1–4]. The proteolytic
complex of the proteasome is represented by a catalytic
20S core particle, a barrel-shaped complex consisting of
four heptameric rings, composed of non-identical α or β
subunits [2, 5, 6]. The catalytic activity is restricted to
three of the beta subunits β1, β2, and β5, which have
specific cleavage preferences, and are constitutively
expressed in most tissues. Under certain conditions as-
sociated with the release of immune-modulatory cyto-
kines (i.e., interferon-γ, IFN-γ), a specialized type of
proteasome called the immunoproteasome can be gen-
erated by the incorporation of the inducible subunits,
β1i (PSMB9; LMP2, low molecular weight protein 2),
β2i (PSMB10; LMP10, MECL-1, multicatalytic endo-
peptidase complex-like 1), and β5i (PSMB8; LMP7, low
molecular weight protein 7) [7, 8]. Increasing evidence
supports a key role of the immunoproteasome in the
regulation of immune cell function, including both the
adaptive and the innate immune response [9–11]. A
deregulation of the immunoproteasome system, with
induction of β1i and β5i subunits in the neurons and/or
glial cells, has been reported in neurodegenerative diseases
([12–14] for review, see [15, 16]). In particular, recent
studies have pointed to the role of immunoproteasome in
glial cells, suggesting a novel interaction between immu-
noproteasome and glia-mediated inflammatory response,
resulting in a pro-inflammatory environment [14, 16].
Interestingly, induction of β1i and β5i subunits has been
also observed in specimens of patients with pharmaco-
resistent mesial temporal lobe epilepsy (MTLE; [17]).
Moreover, recent experimental data support a role for the
β5i subunit in modulating seizure generation in epileptic
tissue, and interestingly, this subunit was not upregulated
in rats exposed to pilocarpine but not developing SE and
spontaneous seizures [18].
In the present study, we investigated the expression
and cellular distribution of both constitutive (β1, β5) and
immunoproteasome (β1i, β5i) subunits using immu-
nohistochemistry in a large cohort of patients with
malformations of cortical development (MCD; including
focal cortical dysplasia (FCD) type II and tuberous scler-
osis complex (TSC) cortical tubers), evaluating a possible
relationship between changes in the expression of these
subunits and the clinical course of epilepsy. To provide
better insights into the mechanisms underlying the astro-
glial regulation of immunoproteasome subunits, we
studied their expression in response to IL-1β stimulation
in both human fetal astrocytes and FCD-derived cells.
Since both FCD II and TSC are associated with constitu-
tive activation of the mammalian target of rapamycin
(mTOR) pathway [19, 20], we further evaluated the ef-
fect of rapamycin (inhibitor of the mTOR pathway) in
FCD II-derived cell cultures.
Methods
Subjects
The cases included in this study were obtained from
the archives of the Departments of Neuropathology of
the Academic Medical Center (AMC, University of
Amsterdam, The Netherlands), the University Medical
Center Utrecht (UMCU, The Netherlands), and the
Medical University Vienna (MUV, Austria). A total of 23
brain tissue specimens, removed from patients undergo-
ing surgery for intractable epilepsy, were examined. The
tissue was obtained and used in accordance with the
Declaration of Helsinki and the AMC Research Code
provided by the Medical Ethics Committee and ap-
proved by the committee of the UMCU Biobank. This
study was also approved by the Ethical Committee of the
Medical University of Vienna. All cases were reviewed
independently by two neuropathologists, and the
diagnosis of FCD was confirmed according to the
international consensus classification system recently
proposed for grading FCD [21]. All patients with cortical
tubers fulfilled the diagnostic criteria for TSC [22]. None
of the FCD patients fulfilled the diagnostic criteria for
TSC. Table 1 summarizes the clinical findings of patients
with MCD and epilepsy (6 mild MCD (mMCD), 5 FCD
IIa, 6 FCD IIb, 6 TSC tubers: 4 TSC2/2 TSC1;
pre-operative seizure frequency/month, mean ± SEM:
mMCD 19.8 ± 6.7; FCD II 149 ± 68.7; TSC 114.8 ± 24.2);
seizure frequencies were recorded (video-electroenceph-
alographic monitoring) at the time of the preoperative
Table 1 Summary of clinical findings of epilepsy patients and controls
Pathology type Number of cases Gender (M/F) Mean age (years/range) Localization Mean duration of epilepsy (years/range)
mMCD 6 5/1 21.5 (19–27) 3 fr/3 t 17.3 (11–32)
FCD IIa 5 3/2 34.2 (18–45) 4 fr/1 t 22.4 (14–26)
FCD IIb 6 2/4 33 (21–45) 4 fr/2 t 24 (15–40)
Cortical tubers (TSC) 6 3/3 7.1 (3–16) 4 fr/2 t 5.8 (0.8–13)
Controls/autopsy 14 8/6 27.0 (2–48) 6 fr/8 t –
FCD focal cortical dysplasia, TSC tuberous sclerosis complex, mMCD mild malformations of cortical development, M male, F female, fr frontal, t temporal
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evaluation. One tuber specimen was obtained postmor-
tem (age 32 years; male; TSC2). Hippocampal specimens
from patients with Alzheimer’s disease (AD; n = 4; 3 fe-
males and 1 male; Braak stages V and VI, age 81.7 ± 2.8)
were also examined as positive controls. In addition,
normal-appearing control cortex and white matter were
obtained at autopsy from six young adult control pa-
tients (Table 1), without history of seizures or other
neurological diseases. All autopsies were performed
within 24 h after death.
Tissue preparation and immunohistochemistry
Brain tissue from control and MCD patients was fixed in
10 % buffered formalin and embedded in paraffin. Paraf-
fin-embedded tissue was sectioned at 5 μm, mounted on
pre-coated glass slides (Star Frost, Waldemar Knittel
GmbH, Braunschweig, Germany), and used for histology
and immunohistochemistry. One representative paraffin
block per case was sectioned, stained, and assessed. Sec-
tions were processed for hematoxylin eosin stainings, as
well as for immunohistochemical stainings for a number
of neuronal and glial markers and antibodies against the
constitutive (β1, β5) and immunoproteasome (β1i, β5i)
subunits (Table 2). These antibodies have been extensively
tested on human liver and brain tissues [23, 24], including
surgical brain specimens from patients with mesial
temporal lobe epilepsy revealing bands at the expected
molecular weight ([17]; Additional file 1: Figure S1). To
detect differences in labeling related to technical variables
such as tissue fixation, we also tested the antibodies in
specimens of selected regions (temporal cortex/hippo-
campus) collected at autopsy and immediately fixed in
formalin for 24 h (same fixation time used for the surgical
specimens); no differences in the immunoreactivity
pattern were observed.
Single-label immunohistochemistry was performed as
previously described [25]. Sections were deparaffinated
in xylene, rinsed in ethanol (100, 95, and 70 %) and in-
cubated for 20 min in 0.3 % hydrogen peroxide diluted
in methanol. Antigen retrieval was performed using a
pressure cooker in 0.1 M citrate buffer pH 6.0 at 120 °C
for 10 min. Slides were washed with phosphate-buffered
saline (PBS; 0.1 M, pH 7.4) and incubated overnight with
the primary antibody in PBS at 4 °C. After washing in
PBS, sections were stained with a polymer-based perox-
idase immunohistochemistry detection kit (PowerVision
Peroxidase System, ImmunoVision, Brisbane, CA, USA).
The 3,3′-diaminobenzidine tetrahydrochloride was used
as chromogen. Sections were dehydrated in alcohol and
xylene and coverslipped.
Double-labeling of β1, β1i, β5, or β5i with NeuN
(neuronal nuclear protein (NeuN; mouse clone MAB377;
Chemicon, Temecula, CA, USA; 1:2000), GFAP (poly-
clonal rabbit, DAKO, Glostrup, Denmark; 1:4000, or
monoclonal mouse, Sigma-Aldrich, St. Louis, MO, USA;
1:4000), HLA-I (mouse clone HC-10, 1:200), or HLA-II
(mouse anti-human leukocyte antigen (HLA)-DP, DQ,
DR, mouse clone CR3/43; DAKO; 1:400) was performed
as previously described [26]). Sections were incubated
with BrightVision poly-alkaline phosphatase (AP)-anti-
rabbit or anti-mouse (Immunologic, Duiven, The
Netherlands) for 30 min at room temperature and
washed with PBS. AP activity was visualized with the AP
substrate kit III Vector Blue (SK-5300, Vector Laborator-
ies Inc., CA, USA). To remove the first primary anti-
body, sections were incubated at 121 °C in citrate buffer
(10 mM NaCi, pH 6.0) for 10 min. Incubation with the
second primary antibody was performed overnight at 4 °C.
Sections with primary antibody other than rabbit were
incubated with post-antibody blocking from the Bright-
Vision+ system (containing rabbit-α-mouse IgG; Im-
munologic, Duiven, The Netherlands). AP activity was
visualized with the alkaline phosphatase substrate kit I
Vector Red (SK-5100; Vector Laboratories Inc., CA,
Table 2 Immunohistochemistry: primary antibodies
Antigen Primary antibody Source Dilution
Glial fibrillary acidic protein (GFAP) Rabbit polyclonal DAKO, Glostrup, Denmark 1:4000
Neuronal nuclear protein (NeuN) Mouse clone MAB377 Chemicon, Temecula, CA, USA 1:2000
Phospho-S6 ribosomal protein (pS6) Ser235/236; rabbit polyclonal Cell Signaling Technology, Beverly, MA, USA 1:50
Interleukin 1β Goat polyclonal Santa Cruz Bio., Delaware CA, USA 1:70
MHC class I (HLA A, B, and C; HLA-I) Mouse clone HC-10 a 1:200
MHC class II (HLA-DP, DQ, DR; HLA-II) Mouse clone CR3/43 DAKO, Glostrup, Denmark 1:400
Proteasome β1 Mouse monoclonal IgG1 Enzo Life Sciences/Biomol, Farmingdale, NY, USA 1:200
Proteasome β5 Rabbit polyclonal Enzo Life Sciences/Biomol 1:500
Proteasome β1i Mouse monoclonal IgG1 Enzo Life Sciences/Biomol 1:200
Proteasome β5i Mouse monoclonal IgG1 Enzo Life Sciences/Biomol 1:200
MHC major histocompatibility complex
aGift from Prof. J. Neefjes, Netherlands Cancer Institute, The Netherlands
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USA). Sections incubated without the primary antibody,
with preimmune sera, or with the antibody preincu-
bated with the antigenic peptide (for the polyclonal β5)
were essentially blank.
Evaluation of histology and immunohistochemistry
All labeled tissue sections were evaluated by two inde-
pendent observers for the presence or absence of various
histopathological parameters and specific immunoreac-
tivity (IR) for the different markers used for the diagno-
sis of mMCD, FCD subtypes, and TSC tubers. We also
semi-quantitatively evaluated the IR (nucleus and cyto-
plasm in glial and neuronal cells) of β1, β1i, β5, and β5i.
The intensity of the staining was evaluated using a scale
of 0–3 (0: no; 1: weak; 2: moderate; 3: strong staining).
All areas of the lesion were examined, and the score rep-
resents the predominant cell staining intensity found in
each case. The frequency of β1, β1i, β5, or β5i positive
cells ((1) rare; (2) sparse; (3) high) was also evaluated to
give information about the relative number of positive
cells within the lesion. We also evaluated intensity and
frequency of pS6 and IL-1β staining. As described in
previous studies [25, 27], the product of the intensity
and frequency scores was taken to give the overall score
(total score; immunoreactivity score (IRS), Table 3).
Quantification of signal intensity using ImageJ software
was performed for β1i and β5i subunits (Additional file
2: Figure S2).
Cell cultures
Primary fetal astrocyte-enriched cell cultures were ob-
tained from human fetal brain tissue (14–19 weeks of
gestation) obtained from the HIS-Mouse (human im-
mune system mouse) facility of the AMC, Amsterdam.
All materials have been collected from donors from
whom a written informed consent for the use of the
material for research purposes had been obtained by
the Bloemenhove Clinic (Heemstede, The Netherlands);
these informed consents are kept together with the
medical record of the donor by the clinic. The tissue
was obtained in accordance with the Declaration of
Helsinki and the AMC Research Code provided by the
Medical Ethics Committee of the AMC. Cell isolation
was performed as described elsewhere [28–30]. Briefly,
after the removal of the blood vessels, the tissue was
mechanically minced into smaller fragments and enzy-
matically digested by incubating at 37 °C for 30 min
with 2.5 % trypsin (Sigma-Aldrich; St. Louis, MO,
Table 3 Immunoreactivity of β1, β1i, β5, and β5i proteasome subunits in the cortex
(Dysmorphic) neurons Glia Balloon/giant cells
Cytoplasm Nucleus Cytoplasm Nucleus Cytoplasm Nucleus
β1 Control 2 (2–3) 0 0 (0–1) 0 – –
mMCD 2▪°~ 1 (1–2)*°~ 0▪°~ 0°~ – –
FCDIIa 5 (4–9)* 1 (1–2)*° 2.5 (2–4)* 2.5 (2–4)*° – –
FCDIIb 7.5 (3–9)* 6 (3–6)* 4 (3–6)* 5 (4–6)* 3.5 (3–6) 6 (4–9)
TSC 6.5 (4–9)* 5 (4–9)* 7.5 (4–9)* 7.5 (4–9)* 6 (3–9) 9 (6–9)
β1i Control 0 (0–1) 0 (0–1) 1 (0–1) 0 (0–2) – –
mMCD 0▪°~ 0▪°~ 0 (0–1)▪°~ 0▪°~ – –
FCDIIa 3 (2–4)* 4 (3–6)*~ 3.5 (3–4)* 3 (3–6)*~ – –
FCDIIb 4 (2–4)* 6 (3–9)* 6 (3–9)* 5 (3–6)* 4 (3–4) 7.5 (3–9)
TSC 3.5 (2–6)* 6 (4–9)* 5 (3–9)* 5 (2–9)* 4 (3–6) 7.5 (4–9)
β5 Control 1 (0–1) 1 (0–1) 0 0 (0–1) – –
mMCD 0°~ 6*▪ 0°~ 0▪°~ – –
FCDIIa 3.5 (2–4)*~ 7.5 (6–9)* 1.5 (0–2)*~ 2.5 (1–4)*~ – –
FCDIIb 6 (4–6)*° 9 (6–9)* 3.5 (3–4)* 6 (4–9)*° 4 (3–6) 9 (6–9)
TSC 3.5 (3–4)* 7.5 (6–9)* 2.5 (2–4)* 2.5 (2–4)* 6 (4–9) 9 (6–9)
β5i Control 0 0 0 (0–1) 1 (1–2) – –
mMCD 0° 0▪~ 0 (0–1)°~ 0°~ – –
FCDIIa 0° 1.5 (1–4)* 0 (0–2)° 0 (0–2)~ – –
FCDIIb 0 (0–1)° 4 (3–6)° 2.5 (1–3)° 3 (1–6) 0 (0–1)° 6 (4–6)°
TSC 6 (4–9)* 0.5 (0–1) 6 (4–9)* 1.5 (1–2)* 9 (6–9) 0.5 (0–1)
Immunoreactivity score (IRS) is given as median (minimum-maximum). IRS is defined as intensity score multiplied by frequency score (see “Methods” section).
Kruskall-Wallis test followed by Mann-Whitney U test
*Different compared to controls; °different compared to TSC; ▪different compared to FCDIIa; ~different compared to FCDIIb, p < 0.05
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USA). The tissue was washed with incubation medium
containing Dulbecco’s modified Eagle’s medium
(DMEM)/HAM F10 (1:1) medium (Gibco, Life Tech-
nologies, Grand Island, New York, USA), supplemented
with 50 units/ml penicillin, 50 μg/ml streptomycin, and
10 % fetal calf serum (FCS; Gibco, Life Technologies,
Grand Island, New York, USA) and triturated by
passing through a 70 μm mesh filter. Cell suspension
was incubated at 37 °C, 5 % CO2 for 48 h to let glial
cells adhere to the culture flask before it was washed
with PBS to remove excess of myelin and cell debris.
Cultures were subsequently refreshed twice a week.
Cultures reached confluence after 2–3 weeks.
Primary FCD astrocyte cultures were derived from a
surgical human brain specimen obtained from a patient
with FCD type IIA (age at surgery, 16 years; female;
location, frontal; seizure frequency, thrice per week;
duration of epilepsy, 11 years) undergoing epilepsy sur-
gery at the Department of Pediatrics/Neurosurgery of
the Medical University Vienna (Vienna, Austria). FCD
astrocyte cultures were established in the same manner
as described above for fetal cultures.
Secondary astrocyte cultures for experimental manipu-
lation were established by trypsinizing confluent cultures
and sub-plating onto poly-L-lysine (PLL; 15 μg/ml,
Sigma-Aldrich)-precoated 12- and 24-well plates (Costar,
Cambridge, MA, USA; 5 × 104 cells/well in a 12-well
plate for RNA isolation and PCR; 2.5 × 104 cells/well for
immunocytochemistry). In the present study, astrocytes
were used for analyses at passages 2–4.
Cell cultures were stimulated with human recombin-
ant (r)IL-1 β (PeproTech, Rocky Hill, NJ, USA; 10 ng/
ml) or in some experiments with lipopolysaccharide
(LPS; 100 ng/ml; Sigma-Aldrich, St. Louis, USA) for
24 h. Treatment of FCD-derived astrocytes with rapamy-
cin (100 nM) was started 24 h before and continued dur-
ing IL-1β stimulation. Cells were harvested 24 h after
stimulation. Viability of human cell cultures was not
influenced by the performed treatments (Additional file
3: Figure S3).
For immunofluorescent staining of cell cultures, sec-
tions were incubated with the primary antibodies for
β1, β1i, β5, or β5i for 1 h at RT, followed by 2 h of incu-
bation at RT with Alexa Fluor® 568-conjugated anti-
rabbit or Alexa Fluor® 488-conjugated anti-mouse IgG
(1:200, Molecular Probes, The Netherlands) together
with Alexa Fluor® 488 or 594 Phalloidin (1:200, Molecu-
lar Probes, Plaats, The Netherlands) for counterstaining
actin filaments. Sections were mounted using VECTA-
SHIELD with DAPI (Vector Laboratories Inc., Burlin-
game, CA, USA). Fluorescent microscopy was
performed using a Leica Confocal Microscope TSC SP-
8X (Leica, Son, the Netherlands) at ×40 magnification
(bidirectional X, speed 600 Hz, pinhole 1.00 AU).
RNA isolation and real-time quantitative PCR analysis
For RNA isolation, cell culture material was homoge-
nized in Qiazol Lysis Reagent (Qiagen Benelux, Venlo,
The Netherlands). Total RNA was isolated using the miR-
Neasy Mini kit (Qiagen Benelux, Venlo, The Netherlands)
according to the manufacturer’s instructions. The con-
centration and purity of RNA were determined at 260/
280 nm using a NanoDrop 2000 spectrophotometer
(Thermo Scientific, Wilmington, DE, USA). To evaluate
β1, β1i, β5 or β5i, and IFNγ mRNA expression, 200 ng
of cell-culture-derived total RNA was reverse-transcribed
into cDNA using oligo dT primers. PCRs were run on a
Roche LightCycler 480 thermocycler (Roche Applied
Science, Basel, Switzerland) using the following primers:
β1 (forward: accagctcggtttccaca, reverse: cccggtatcgg
taacacatc); β5 (forward: gagtctcagtgatggtctgagc, reverse:
actccatggcggaacttg); β1i (forward: accaaccggggacttacc,
reverse: tcaaacactcggttcaccac); β5i (forward: ccctacc
cacccctgttt; reverse: cacccagggactggaaga); and IFN-γ
(forward: gcaagatcccatgggttgtgt; reverse: ctggctcagattg
caggcata). Quantification of data was performed using the
computer program LinRegPCR in which linear regression
on the log (fluorescence) per cycle number data is applied
to determine the amplification efficiency per sample
[31, 32]. The starting concentration of each specific
product was divided by the geometric mean of the
starting concentration of the reference genes (EF1α and
C1orf43), and this ratio was compared between groups.
Statistical analysis
Statistical analyses were performed with GraphPad
Prism software (Graphpad Software Inc., La Jolla, CA,
USA). To assess differences in immunoreactivity score
between multiple groups, non-parametric Kruskal-Wallis
followed with Mann-Whitney U test was used. Correla-
tions were assessed using Spearman’s (rho) rank correl-
ation test. For cell culture data, Mann-Whitney U test was
used to asses differences between different conditions.
P<0.05 was assumed to indicate a significant difference.
Results
Case material and histological features
The clinical features of the cases included in this study
are summarized in Table 1. All operated patients had a
history of chronic pharmacoresistant epilepsy. In this
study, we included patients with mild degree of cortical
dysplasia (mMCDs; [33]). Age at surgery, seizure
duration, and seizure frequency were not statistically
different between patients with FCD II and mMCD in
this cohort, as well as between the FCD IIa and FCD IIb
cases included in our cohort. Accordingly to the
international consensus classification system of FCD
[21], FCD II represents isolated focal lesions with archi-
tectural and dysmorphic abnormalities (FCD IIa with
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dysmorphic neurons only; FCD IIb with dysmorphic
neurons and balloon cells; Figs. 1, 2, 3, and 4c–e). TSC
patients were younger compared to mMCD and FCD
patients. All six TSC tubers displayed similar histopatho-
logical features, including loss of lamination, astrogliosis,
dysmorphic neurons, and giant cells with pale eosino-
philic cytoplasm ([34]; Figs. 1, 2, 3, and 4f, g).
Proteasome subunit expression in FCD and cortical tubers
Expression of β1, β1i, β5, and β5i was observed in FCD,
cortical tubers, and mMCD specimens (Figs. 1, 2, 3, and 4;
Additional file 2: Figure S2 and Additional file 4: Figure
S4). We observed differences in the expression level as
well as in the cell-specific and subcellular distribution
of the different subunits (Table 3).
Constitutive proteasome catalytic subunit β1 and β5
Moderate expression of β1 and β5 subunits was ob-
served in human control cortical specimens (Figs. 1a, b
and 3a, b; Table 3). Nuclear neuronal expression was de-
tected for β5 in MCD specimens (Table 3; Additional file
4: Figure S4E); whereas only cytoplasm expression was
detected in specimens from patients with Alzheimer’s
disease for both subunits (Additional file 4: Figure S4B, F).
Fig. 1 β1 proteasome subunit immunoreactivity in control, focal cortical dysplasia (FCD) type IIa, FCD type IIb, and tuberous sclerosis complex
(TSC). Panels a, b (control) show weak immunoreactivity (IR) in both the cortex (a insert: neuron with weak expression of β1 subunit) and white
matter (b not-detectable glial expression). Panel c (FCD IIa) shows positive dysmorphic neurons (arrows; insert: high magnification) and glial cells
(arrow heads). Panels d–e (FCD IIb) show several β1 positive cells within the cortex (d) and white matter (e), including the dysmorphic neurons
(arrows in d), glial cells (arrow heads and insert in d) and balloon cells (arrows in e; prominent nuclear expression; insert: high magnification).
Panels f–g (TSC tuber): β1 subunit expression is observed within the tuber in dysmorphic neurons (arrows in f; insert a: co-localization with
the neuronal marker NeuN; insert b, co-localization with GFAP), glial cells (arrow heads in f) and in giant cells (asterisk (g); insert: co-localization
with GFAP). Additional examples of the different cell types at higher magnification in separate specimens. The inserts within panels show
imagines of the different cells types at higher magnification in separate specimens. Scale bar in G: A–C, E–F: 80 μm; D–G: 40 μm
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Increased expression of both constitutive subunits was ob-
served in FCD and TSC specimens (Figs. 1c–g and 3c–g;
Table 2). In the large majority of FCD and TSC cases, β1
IR was detected in the cytoplasm and nucleus of neuronal
and glial cells (Fig. 1c–g; Table 3). β1 was also detected in
the balloon (FCD IIb; Fig. 1e) and giant cells (TSC; Fig. 1g).
FCD and TSC specimens displayed also strong β5 IR with
prominent nuclear expression in both neuronal and glial
cells, as well as in the balloon (FCD IIb) and giant cells
(TSC; Fig. 3c–g; Table 3). A similar pattern was detected
in the postmortem TSC case; double-labeling experiments
confirmed the co-localization with astroglial and neuronal
markers within the dysplastic area for both subunits in
FCD and TSC specimens (Figs. 1f–g and 3g).
Immunoproteasome subunits β1i and β5i
In the large majority of control (Figs. 2a, b and 4a, b)
and mMCD (Additional file 4: Figure S4C, G) specimens,
the immunoproteasome subunits β1i and β5i were under
the detection levels in both neuronal and glial cells
(Table 3). β1i and β5i were consistently high in FCD and
TSC specimens (Table 3; Additional file 2: Figure S2)
Fig. 2 β1i proteasome subunit immunoreactivity in control, focal cortical dysplasia (FCD) type IIa, FCD type IIb, and tuberous sclerosis complex
(TSC). a, b Control cortex (a) and with matter (b) with weak β1i expression (insert in a: negative neuron, high magnification). Panel c (FCD IIa)
shows strong expression within the dysplastic region with positive dysmorphic neurons (arrows; inserts: a nuclear expression; b cytoplasmic
expression) and glial cells (insert in c). Panels d–e (FCD IIb) show several β1i-positive cells within the cortex (d) and white matter (e), including
dysmorphic neurons (arrow in d), glial cells (arrow heads d and e), and balloon cells (arrows in e; nuclear and cytoplasmic expression; insert:
co-localization with the pS6). Panels f, g (TSC tuber): β1i subunit expression is observed within the tuber in dysmorphic neurons (f arrows, nuclear
expression; arrow head, cytoplasmic expression; insert a in f: co-localization with the neuronal marker NeuN; insert b in f: co-localization with the
pS6; insert c: co-localization with HLA-II), glial cells (insert b in g), and in giant cells (arrows in g; insert b: co-localization with GFAP; insert c:
co-localization with HLA-I). The inserts within the panels show images of the different cell types at higher magnification in separate specimens.
Scale bar in g: a–c: 80 μm; d–g: 40 μm
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with strong cytoplasmic and nuclear IR in neuronal and
glial cells, in both surgical postmortem TSC specimens
(whereas only cytoplasmic expression was detected in
glial cells in specimens from patients with Alzheimer’s
disease for both β1i and β5i subunits; Additional file 4:
Figure S4D, H). A similar pattern with strong expres-
sion in FCD and TSC specimens was observed using in
situ hybridization (Additional file 5: Figure S5). Double-
labeling experiments confirmed the co-localization with
astroglial and neuronal markers, as well as with major
histocompatibility complex (MHC) class I (HLA-I; in
few balloon/giant cells and in dysmorphic neurons)
within the dysplastic area for both subunits in FCD
and TSC specimens (Figs. 2 and 4f, g). In regions with
prominent activation of microglia, IR for both β1i and
β5i was also observed in cells of the microglia/macro-
phage lineage (HLA-II; Figs. 2 and 4). The balloon
(FCD IIb; Fig. 2e) and giant cells (TSC; Fig. 4g) dis-
played β1i and β5i IR as well (Table 2). Co-localization
was observed for both β1i and β5i with pS6 (Figs. 2
and 4). β1i and β5i expression in neurons was posi-
tively associated with pS6 expression within our MCD
Fig. 3 β5 proteasome subunit immunoreactivity in control, focal cortical dysplasia (FCD) type IIa, FCD type IIb, and tuberous sclerosis complex
(TSC). Panels a and b: (control) show the weak immunoreactivity in both the cortex (a insert: neuron) and white matter (b not detectable glial
expression). Panel c (FCD IIa) shows positive dysmorphic neurons (arrows; insert: high magnification, nuclear expression). Panels d and e (FCD IIb)
show several β5 positive cells within the cortex (d) and white matter (e), including dysmorphic neurons (arrows in d and insert, nuclear and
cytoplasmic expression), glial cells (arrow heads and insert in d), and balloon cells (asterisk in e; insert: high magnification, with prominent
nuclear expression). Panels f and g (TSC-tuber): β5 subunit expression is observed within the tuber in dysmorphic neurons (arrows in f; insert
b in panel g: co-localization with the neuronal marker NeuN; insert c in panel g, co-localization with GFAP) and in giant cells (arrow in g and
insert a; insert b: co-localization with NeuN; insert c: expression in glial cells, co-localization with GFAP). The inserts within panels show images
of the different cell types at higher magnification in separate specimens. Scale bar in g: a–c, g: 80 μm; d–f: 40 μm
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cohort (β1i cytoplasm, r = 0.5905, p = 0.030; β1i nu-
cleus, r = 0.6244, p = 0.0014; β5i cytoplasm, r = 0.4510,
p = 0.0065). A positive correlation was detected be-
tween β1i and β5i expression in neurons and glial cells
and IL-1β IRS within the dysplastic region (neuronal
β1i cytoplasm, r = 0.4287, p = 0.0413; neuronal β1i
nucleus, r = 0.5090, p = 0.0131; glia β1i cytoplasm, r =
0.5298, p = 0.0093; glia β1i nucleus, r = 0.6091, p = 0.0003;
neuronal β5i cytoplasm, r = 0.7322, p = <0.001; glia
β5i cytoplasm, r = 0.7005, p = <0.001; glia β5i nucleus,
r = 0.4210, p = 0.0455).
Immunoproteasome subunit expression and clinical features
We found no statistically significant association between
the IRS of β1, β1i, β5 or β5i, and clinical features, such
gender, age at surgery, location of the lesion, or duration
of epilepsy. However, a positive correlation was observed
between nuclear glial and neuronal subunit expression
and the pre-operative seizure frequency (β1 and β1i
neuron τ = 0.639 and τ = 0.633, p < 0.001; β1 and β1i glia
τ = 0.479, p = 0.005 and τ = 0.65, p < 0.001; β1 and β1i
neuron τ = 0.550, p = 0.004 and τ = 0.417, p = 0.016; β1
and β1i glia τ = 0.570, p = 0.001; τ = 0.586, p = 0.001).
Fig. 4 β5i proteasome subunit immunoreactivity in control, focal cortical dysplasia (FCD) type IIa, FCD type IIb, and tuberous sclerosis complex
(TSC). Panels a and b: control cortex (a) and with white matter (b) with weak β5i expression. Panel c (FCD IIa) shows expression within the
dysplastic region with positive dysmorphic neurons (arrows and insert, nuclear expression) and glial cells (arrow heads). Panels d and e (FCD IIb)
show several β5i-positive cells within the cortex (d) and white matter (e), including dysmorphic neurons (arrow in d), glial cells (arrow heads d
and e; insert in d), and balloon cells (arrows in e; insert: co-localization with pS6). Panels f, and g (TSC-tuber): strong β5i subunit expression is
observed within the tuber in dysmorphic neurons (f arrows and inserts a and b; b co-localization with the neuronal marker NeuN; c co-localization
with the pS6; d co-localization with HLA-II), glial cells (arrows in g; insert in g, co-localization with GFAP), and in giant cells (arrows in h; insert:
co-localization with HLA-I). The inserts within the panels show images of the different cell types at higher magnification in separate specimens.
Scale bar in h: a–c 80 μm; d–h 40 μm
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Regulation of immunoproteasome subunit expression in
human glial cells in culture
Since IL-1β is known to be strongly upregulated in
FCD and TSC human brain specimens [27, 34, 35]
and to play a key pathogenic role in human epilepsy
(for review, see [20, 36]; we also investigated whether
this inflammatory cytokine could play a role in the
regulation of the expression and cellular localization
of immunoproteasome subunits. qPCR analysis of
astrocyte-enriched human fetal cell cultures demon-
strated that exposure to IL-1β did not modify the
expression of the constitutive subunits (Fig. 5a, d) but
did consistently increase the expression of both
immunoproteasome subunits β1i and β5i (Fig. 5b, e),
increasing the β1/ β1i and β5/β5i ratios (Fig. 5c, f ).
Treatment with LPS, also a potent inducer of the immune
response, gave comparable results (Fig. 5). Exposure
to IL-1β and LPS did not significantly affect the
expression of IFNγ in these cultures. Immuno-
histochemistry showed a translocation of the β1i and
β5i subunits, shifting from cytoplasmic to perinuclear-
nuclear expression following IL-1β treatment (Fig. 6d, h).
Effects of rapamycin on proteasome subunit expression in
FCD II-derived astrocytes
Since both FCD II and TSC are associated with constitu-
tive activation of the mTOR pathway [19, 20], we inves-
tigated whether the canonical and allosteric mTOR
kinase rapamycin modulates the immunoproteasome in
cell cultures derived from FCD II specimens. Western
blot analysis confirmed that 100 nM rapamycin reduced
the phosphorylation of S6 (pS6) in human astrocytes, an
indicator of mTOR activation (Additional file 3: Figure
S3). Pretreatment with 100 nM rapamycin reduced the
mRNA expression of β1 and β1i subunits under both
unstimulated and stimulated conditions (Fig. 7a, b). β5
and β5i expression was reduced by rapamycin in the
presence of IL-1β (Fig. 7c, d). Immunocytochemical
analysis of these FCD cells confirmed the negative
modulation of proteasome subunits by rapamycin (Fig. 8).
Discussion
The present study reports in detail the expression
pattern and cellular localization of the constitutive
and immunoproteasome subunits in FCD II and TSC
A B C
D E F
Fig. 5 Effects of IL-1β and LPS stimulation on immunoproteasome subunit expression in cell culture. Quantitative real-time PCR of proteasome
expression in human fetal astrocytes after the 24 h exposure to IL-1β (10 ng/ml) or LPS (100 ng/ml). a, b, d, e Stimulation with IL-1β or LPS
increased expression of the β1i (b) and the β5i (e) subunits compared to control, but not of the constitutive β1 (a) and β5 (d) subunits.
c, f Stimulation with either IL-1β or LPS increased the β1i/β1 (c) and the β5i/β5 (f) ratios. Data are expressed relative to the levels observed in
untreated cells and are mean ± SEM (n = 5). **p < 0.01, ***p < 0.001 compared to control, Mann-Whitney U test
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cortical tubers and mMCD. The cell-specific distribu-
tion of proteasome subunits in relation with the
epileptogenicity of these developmental lesions as well
as their regulation in human astrocytes is discussed in
the following paragraphs.
Proteasome subunits expression in malformations of
cortical development: prominent expression in FCD II
and TSC
Our data show prominent expression of both constitu-
tive and immunoproteasome subunits in MCD, such as
FCD and TSC, associated with the mTOR pathway. In
all the FCD II and TSC specimens examined, the IR for
β1, β1, β5, and β5i was increased within the dysplastic
regions where prominent gliosis and the presence of
dysmorphic neurons and balloon or giant cells (in FCD
IIb and TSC, respectively) was observed. Constitutive
and particularly immunoproteasome subunits displayed
increased expression compared to control but also
compared to mMCD specimens from patients with
chronic epilepsy. These results indicate that increased
expression of proteasome subunits is not simply an
effect of seizure activity; moreover, the duration of
epilepsy in mMCD cases did not differ from FCDs and
was even longer compared to TSC cases. However, a
positive correlation was observed between nuclear glial
and neuronal proteasome subunit expression and the
pre-operative seizure frequency. We acknowledge limi-
tations to the interpretation of these results; therefore,
an evaluation of the real biological contribution of pro-
teasome subunit expression to seizure generation and
frequency deserves further investigation in experimen-
tal models.
Several proteasome subunits show nuclear localization
signaling [37], and previous studies in the human brain
indicate that proteasomes are expressed in both cyto-
plasm and nuclei of different cell types, including glial
and neuronal cells [24, 38]. Immunoproteasome expres-
sion restricted to nuclei of astrocytes has been reported
in the brain after an infection with lymphocytic chorio-
meningitis virus, suggesting involvement of the nuclear
envelope in the compartmentalization of immature pro-
teasome precursors [39]. Whether the nuclear prote-
asome subunits represent (as suggested by Kremer et al.
[39]) immature proteasome precursors or are proteo-
lytically active remains still to be investigated. The nu-
clear proteasome subunit accumulation may reflect the
induction of the proteasome system under conditions
associated with cell injury and inflammation with the
possibility of nucleo-cytoplasmic transfer in cells, as glial
cells, undergoing cell division or during apoptosis [37].
However, the β1i subunit in the nuclear-enriched frac-
tion has also been detected in its catalytically active form
[40], and several studies indicate a possible functional
role of the immunoproteasome in transcriptional regula-
tion [41–43]. The expression pattern, either nuclear or
cytoplasmic proteasome expression, can be influenced
by the type and duration of fixation [37]. However,
similar pattern was observed in surgical and postmor-
tem TSC brain tissue.
Fig. 6 Effects of IL-1β stimulation on proteasome subunit expression
in astrocytes in cell culture. Expression of β1 (a and b; green), β1i (c and
d; green), β5 (e and f; red), and β5i (g and h; green) in unstimulated
human fetal astrocytes (left panels) and in astrocytes after exposure
to IL-1β (24 h; 10 ng/ml, right panels); increased expression of all subunits
was observed. A translocation of particularly the β1i and β5i subunits,
shifting from cytoplasmic to perinuclear-nuclear expression following
IL-1β treatment was observed. Cells were counterstained with phalloidin
(actin filaments; red in a–d and g–h, green in e and f) and diamidino-2-
phenylindole, DAPI (nuclei; blue). Scale bar in a: 15 μm
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One of the major regulatory factors of immunoprotea-
some induction is inflammation [43, 44]. Several studies
confirmed the occurrence of complex inflammatory
changes, involving both glial and neuronal cells, and the
activation of the IL-1β pathway, particularly in FCD II and
TSC [20, 34, 35, 45–48]. Thus, the pro-inflammatory
environment may contribute to the activation of the pro-
teasome system, particularly to the induction and expres-
sion of the immunoproteasome subunits. Accordingly,
our in vitro studies in human astrocytes and FCD cultures
indicate that IL-1β treatment increases the induction of,
in particular, the immunoproteasome subunits β1i and
β5i, with the increase of their perinuclear-nuclear
localization. This observation supports the role of astro-
cytes as targets of regulation of the immunoproteasome
under various conditions associated with the activation
of the IL-1β pathway [16] and indicates that pro-
inflammatory cytokines, other than IFNγ, may regulate
immunoproteasome expression. Activation of inflam-
matory pathways, including IL-1β, may also play a role
in the regulation of immunoproteasome expression in
other cell types, such as neurons. Accordingly, we
found a positive correlation between the expression of
immunoproteasome subunits in both glial and neuronal
cells and the expression of IL-1β within the dysplastic
area in FCD II and in TSC specimens. Moreover,
increasing evidence supports the role of the immuno-
proteasome in the activation of the NF-kB pathway,
modulation of pro-inflammatory cytokine production,
and oxidative stress response [9, 43, 49–52]. Induction
of the β5i subunit has also been shown in vivo following
activation of the Toll-like receptor 4 (TLR4)-mediated
NF-kB signaling pathway by LPS [53]. Thus, we may
speculate about the existence of a reinforcing feedback
loop between NF-kB pathway and the immunoproteasome
system, which may play a crucial role in perpetuating the
pro-epileptogenic inflammatory response in epilepsy.
Interestingly, Mishto et al. [18] provide additional
experimental evidence of the regulation of β5i subunit
by TLR4 signaling in epileptogenic tissue.
The immunoproteasome is known to improve MHC
class I (MHC-I) antigen presentation and has been sug-
gested to have a central function at the interface between
the innate and adaptive immune system (reviewed in
[11]). Interestingly, FCD II and TSC specimens are
characterized by prominent activation of both innate and
adaptive immune responses (for review, see [20, 36]).
Moreover, recent studies provide evidence of an upregula-
tion of MHC-I, involving also balloons/giant cells and
neurons, in both FCD II and TSC specimens [54].
FCD II and TSC cases are characterized by architec-
tural or cellular changes associated with mTOR pathway
activation [20, 21]. The innate and adaptive immune
responses have also been shown to be influenced by the
mTOR pathway [55–57]. Moreover, the mTOR complex
1 (mTORC1) has been identified as a key regulator of
Fig. 7 Effects of rapamycin on proteasome subunit expression in astrocytes derived from FCD type II. Quantitative real-time PCR of proteasome
expression in human FCD cells after 48 h treatment with 100 nM rapamycin, under basal and stimulated (IL-1β 10 ng/ml) conditions. a, b Treat-
ment with rapamycin decreased the expression of β1 (a) and β1i (b) subunit, both in the basal and under stimulated conditions. c, d Treatment with
rapamycin decreased the expression of β5 (c) and β5i (d) subunit under stimulated, but not in basal conditions. Data are expressed relative to
the levels observed in untreated cells and are mean ± SEM (n = 5). *p < 0.05, **p < 0.01 compared to control, Mann-Whitney U test
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autophagy [58, 59], a pathway which is defective in FCD
II and TSC [60]. Increasing evidence indicates a strong
relationship with tight coordination between the auto-
phagy and the proteasome system [61]. Thus, we cannot
exclude a role of mTOR in the regulation of the prote-
asome system, including immunoproteasome subunit
expression. Accordingly, we observed a positive correl-
ation between immunoproteasome subunit expression in
neurons and pS6 expression, indicating the activation of
the mTOR signal transduction pathway. The relationship
between mTOR and proteasome system is also sup-
ported by the in vitro experiments showing that inhib-
ition of the mTOR pathway by the potent allosteric
mTORC1 inhibitor rapamycin was able to reduce the
level of expression of inducible proteasome subunits in
FCD-derived cells. This is in agreement with a recent
study showing reduction of the immunoproteasome by
rapamycin in H9c2 cells as well as in mouse heart in
vivo [62]. Evaluation of the possible effect of rapamycin
on the expression of the brain immunoproteasome in
vivo deserves further studies and is presently under
investigation [63].
Immunoproteasome inhibition as therapeutic strategy?
An example of the possible use of inhibition of the
immunoproteasome as therapeutic strategy in epilepsy is
represented by the study of Mishto and colleagues [18]
in which specific inhibition of the β5i subunit by ONX-
0914 [64] resulted in prevention, or significant delay, of
4-aminopyridine-induced seizure-like events in acute
rat hippocampal/entorhinal cortex slices, particularly in
slices of epileptic rats. Clinically approved proteasome
inhibitors targeting the catalytic activity of both the
constitutive proteasome and the immunoproteasome
have been already used in hematological malignancies
[65–67]. New-generation small molecules specifically
targeting the immunoproteasome are under clinical
development and have been already evaluated in a large
variety of animal models of autoimmune diseases and
proposed as novel therapeutic approaches for patient
with multiple sclerosis, as well as in neurodegenerative
diseases (for reviews, see [16, 68, 69]).
However, recently alternative functions for the immu-
noproteasome have also been considered, suggesting that
the induction of the immunoproteasome may also play a
role in neuronal protection and repair after injury,
contributing to the preservation of cell viability upon
cytokine-induced oxidative stress [49, 70, 71], which is
known to be increased within the TSC tubers [72]. In
particular, evidence has been provided that the immuno-
proteasome plays a role in the clearance of damaged
proteins accumulating upon inflammation or oxidative
stress (for review, see [49]), which are also detected in
TSC and FCD [73]. Accordingly, the formation of
aggresome-like-induced structures and increased sensi-
tivity to apoptosis has been reported in immunoprotea-
some deficiency in cells and in a murine inflammation
model [49, 71]. Additional studies support alternative
physiological function of the immunoproteasome sub-
units, including also cell proliferation, cell signaling,
Fig. 8 Effects of rapamycin treatment on proteasome subunit
expression in FCD type II derived cells. Expression of β1 (a and b;
green), β1i (c and d; green), β5 (e and f; red), and β5i (g and h; green)
in untreated FCD cells (left panels) and in FCD cells after 48 h of
treatment with 100 nM rapamycin (right panels). Expression of all
subunits was decreased after treatment with rapamycin. Cells were
counterstained with phalloidin (actin filaments; red in a–d and g–h,
green in e and f) and diamidino-2-phenylindole, DAPI (nuclei; blue).
Scale bar in a: 15 μm
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and synaptic remodeling (for review, see [49, 74, 75]).
Thus, an effective therapeutic intervention based on
the immunoproteasome has to take into consideration
the preservation of the potential beneficial functions of
its activation, particularly during brain development.
Conclusions
One important question is whether the activation of the
immunoproteasome system in the brain tissue may per
se be responsible for an increased susceptibility to seizure
activity observed in FCD and TSC. As discussed above,
experimental studies in the hippocampal/entorhinal
cortex slices suggest that the pharmacological inhibition
of the β5i subunit may modulate seizure activity. Whether
these findings can be translated to other experimental
models, including models of FCD and TSC, deserves
further investigation.
To conclude, our observations support the occurrence
of a prominent deregulation of the proteasome system
in MCD. In particular, the induction of immunoprotea-
some subunits in both glial and neuronal cells appears
to be a feature of FCD II and TSC and may represent an
important accompanying feature of the immune response
in these developmental lesions. Therefore, understanding
the role of the immunoproteasome in epilepsy-associated
pathologies may have great importance in view of the
development of new therapeutic strategies.
Additional files
Additional file 1: Figure S1. Representative immunoblot analysis of total
homogenates from (n = 3) surgical hippocampal specimens; β-subunits
(β1, ~25 kDa; β1i, ~22 kDa; β5, ~25 kDa; β5i, ~25 kDa; β-actin ~42 kDa).
(JPG 134 kb)
Additional file 2: Figure S2. β1i and β5i intensity signal in control,
mMCD, FCDII, and TSC. FCD: focal cortical dysplasia; TSC: tuberous sclerosis
complex; mMCD: mild malformations of cortical development. (PPTX 61 kb)
Additional file 3: Figure S3. Effect of the different treatments on fetal
astrocyte cell cultures. A: scatterplots of eFluor viability dye staining as
analyzed by flow cytometry after different treatments. B: Quantification of
viable cells based on eFluor viability staining. Neither treatment with IL-1β
nor rapamycin negatively influenced viability of cell cultures. C: Western
blot analysis showed effective reduction of phosphorylated S6 after 24 h
of 100 nM rapamycin treatment. FSC: forward scatter. (JPG 1420 kb)
Additional file 4: Figure S4. Proteasome subunit immunoreactivity (β1,
β1i β5, and β5i) in mild MCD (mMCD) and in Alzheimer’ s disease (Alz).
Panels A, C, E, and G: mMCD. A: low β1 expression (insert: high magnification
of a neuron, with weak nuclear expression). C: low β1i expression (insert:
high magnification of a neuron). E: nuclear expression of β5 (arrows;
neuron in insert). G: low β5i expression (neuron in insert). Panels B, D, F,
and H (Alz; hippocampus). B: β1 expression in neurons (CA1; arrows,
cytoplasmic expression) and around amyloid plaques (arrow-heads); D: β1i
expression in glial cells (arrows, cytoplasmic expression). F: low β5
expression in neuronal cells (arrows). H: β5i expression in glial cells (arrows,
cytoplasmic expression). Scale bar in B: A, C, F, and G: 80 μm; B, D, and H:
40 μm. (JPG 2799 kb)
Additional file 5: Figure S5. In situ hybridization of β1i and β5i,
proteasome subunit immunoreactivity in control, focal cortical dysplasia
(FCD) type IIb, and tuberous sclerosis complex (TSC). Panels A–D: control
cortex (A–C) and with matter (B–D); β1i (A–B) and β5i (C–D). Panels E–F
(FCD IIb) and panels C–G (TSC) shows strong expression within the
dysplastic region with several positive dysmorphic neurons (arrows and
inserts in E (a) and F), giant cells (inserts in G and H (a)), and glial cells
(inserts (b) in E and H). Scale bar in H: A–H: 80 μm. (JPG 3206 kb)
Additional file 6: Supplementary methods: flow cytometric analysis, in
situ hybridization, Western blot analysis and image quantification. (DOC
46 kb)
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